N
Neurosoft Bioelectronics
Improving the care of patients who suffer from neurological disorders by developing soft implantable electrodes to interface with the nervous system
About Neurosoft Bioelectronics
Neurosoft Bioelectronics is a Swiss medtech company developing soft, stretchable implantable electrodes that interface with the nervous system for recording and stimulation. Its SOFT ECoG and related devices are aimed at identifying epileptogenic tissue in drug-resistant epilepsy and at neuromodulation applications such as tinnitus (SOFT TINNIT), seeking safer contact with neural tissue than conventional stiff clinical electrodes. In May 2026 Neurosoft closed an oversubscribed $7.5 million seed round led by Skybound Venture Capital, with PL Capital, IAG Capital Partners and Connecticut Innovations participating, bringing total funding above $20 million to advance stretchable, scalable brain–computer interface technology. Sources: Business Wire / Morningstar 20 May 2026; MassDevice; Inside BCI 22 May 2026.
Source: Dealroom company dataAt a glance
- Founded
- 2019
- Headquarters
- Geneva, Switzerland
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
MassChallenge
Innosuisse
Kickfund
Series A6 investors entered at this stage
Venture Kick
FONGIT
Skybound Venture Capital
Connecticut Innovations
Protocol Labs
IAG Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neurosoft Bioelectronics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neurosoft Bioelectronics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.